Track topics on Twitter Track topics that are important to you
Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...
* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima
More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More-
* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug
The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More-
The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.
Celltrion deal and multi-million Euro German plant will make it a major second and third wave biosimilars player says Teva.
Celltrion is confident that 2017 will bring European approval and a US filing for Truxima, after achieving regulatory success for the Rituxan biosimilar in Korea.